Modulators of Sestrin-GATOR2 interaction and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
1. A method of treating treatment-resistant depression in a patient in need thereof, said method comprising administering to said patient a compound of formula I-90 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof:
in combination with an antidepressant therapeutic agent.
2. The method of claim 1 , wherein the antidepressant therapeutic agent is an antidepressant selected from bupropion, venlafaxine, mirtazapine, duloxetine, amitriptyline, and imipramine.
3. The method of claim 1 , wherein the antidepressant therapeutic agent is an antidepressant selected from selegiline, nortriptyline, trazodone, desvenlafaxine, and aripiprazole.
4. The method of claim 1 , wherein the antidepressant therapeutic agent is a selective serotonin reuptake inhibitor (SSRI).
5. The method of claim 4 , wherein the SSRI is selected from sertraline, escitalopram, citalopram, fluvoxamine, fluoxetine, and paroxetine.
6. The method of claim 4 , wherein the SSRI is sertraline.
7. The method of claim 4 , wherein the SSRI is escitalopram.
8. The method of claim 4 , wherein the SSRI is citalopram.
9. The method of claim 4 , wherein the SSRI is fluvoxamine.
10. The method of claim 4 , wherein the SSRI is fluoxetine.
11. The method of claim 4 , wherein the SSRI is paroxetine.
12. The method of claim 1 , wherein the compound of formula I-90 and the antidepressant therapeutic agent are administered in combination to the patient in need thereof simultaneously or sequentially.
13. The method of claim 1 , wherein the compound of formula I-90 and the antidepressant therapeutic agent are administered in combination to the patient in need thereof in separate unit dosage forms or together in a single unit dosage form.
14. The method of claim 1 , wherein the pharmaceutically acceptable composition comprising a compound of formula I-90 further comprises a pharmaceutically acceptable carrier, adjuvant, or vehicle.
15. The method of claim 1 , wherein the pharmaceutically acceptable composition comprising a compound of formula I-90 and an antidepressant therapeutic agent further comprises a pharmaceutically acceptable carrier, adjuvant, or vehicle.
16. The method according to claim 1 , wherein the treatment-resistant depression is resistant to first line treatments.
17. The method according to claim 1 , wherein the treatment-resistant depression is resistant to second line treatments.